# DESCRIPTION

## BACKGROUND

- motivate therapeutic agents

## SUMMARY

- describe method of modulating OPA1 protein expression
- introduce agent or vector encoding agent
- modulate splicing of NMD exon
- modulate level of processed mRNA
- modulate expression of OPA1 protein
- specify agent binding to targeted portion of pre-mRNA
- modulate binding of factor involved in splicing
- interfere with factor binding to targeted portion
- specify targeted portion proximal to NMD exon
- specify targeted portion upstream or downstream of NMD exon
- specify targeted portion within NMD exon
- describe NMD exon sequence identity
- describe method promoting exclusion of NMD exon
- describe method increasing level of processed mRNA
- describe method increasing expression of OPA1 protein
- summarize method
- describe OPA1 protein
- motivate agent
- describe antisense oligomer
- describe gene editing molecule
- describe method of modulating expression
- describe target portion of pre-mRNA
- describe coding exon
- describe method of modulating expression of target protein
- summarize embodiments of coding exon
- specify targeted portion of pre-mRNA
- describe exclusion of coding exon
- describe exclusion of NMD exon
- specify increase in processed mRNA level
- specify increase in target protein expression
- describe functional OPA1 protein
- specify antisense oligomer composition
- describe gene editing molecule composition
- specify backbone modification
- specify sugar moiety modification
- describe vector composition
- describe pharmaceutical composition
- specify therapeutic agent promotion
- describe method of treating disease
- specify disease or condition association
- describe subject administration
- specify administration route
- describe treatment outcome

## DETAILED DESCRIPTION

- introduce therapeutic agents for OPA1 protein deficiency

### mRNA Splicing

- describe mRNA splicing process
- explain spliceosome assembly
- discuss auxiliary sequences and structures
- introduce stochastic modeling of splicing
- describe exonic and intronic splicing regulatory elements
- explain roles of SR proteins and hnRNP family
- define alternative splicing and its regulation
- discuss alternatively spliced exons and their inclusion
- explain nonsense-mediated mRNA decay (NMD) pathway
- introduce NMD-inducing exons and cryptic splice sites

### Target Transcripts

- introduce OPA1 gene and NMD exon
- describe splicing of OPA1 pre-mRNA to produce functional OPA1 mRNA
- motivate alternative splicing of OPA1 pre-mRNA
- describe modulation of OPA1 protein expression by exon skipping
- introduce therapeutic agent for modulating OPA1 protein expression
- describe targeting of OPA1 pre-mRNA by therapeutic agent
- introduce ASO as therapeutic agent
- describe targeting of NMD exon by ASO
- describe targeting of sequence upstream of NMD exon by ASO
- describe targeting of sequence downstream of NMD exon by ASO
- describe targeting of exon-intron boundary by ASO
- describe targeting of exon or intron by ASO
- describe sequence identity of OPA1 NMD exon-containing pre-mRNA transcript
- describe targeting of specific exons (e.g. exon 6x, exon 7x, exon 28x) by ASO
- describe targeting of specific regions of OPA1 pre-mRNA by ASO
- describe sequence complementarity of ASO to targeted portion of NMD exon mRNA
- define target transcripts
- specify ASO targets
- describe exon skipping
- detail pseudo-exon targets
- specify coding exon targets
- describe upstream targets
- describe downstream targets
- specify intron targets
- describe exon-intron boundary targets
- specify sequence identity requirements
- detail OPA1 pre-mRNA transcript targets
- specify ASO target regions
- describe ASO sequence complementarity

### Protein Expression

- define functional OPA1 protein
- define partially functional OPA1 protein
- describe method of increasing OPA1 protein expression
- describe method of increasing OPA1 protein expression in haploinsufficiency
- describe method of increasing OPA1 protein expression in autosomal recessive inheritance
- describe method of increasing OPA1 protein expression in autosomal dominant inheritance
- describe targeting of pre-mRNA transcript by ASO
- describe increase in mRNA encoding OPA1 protein

### Exon Inclusion

- define NMD exon-containing pre-mRNA
- describe alternative splicing
- explain inclusion of pseudo-exon
- define mature mRNA
- describe NMD of mature mRNA
- explain exon skipping
- calculate percent exon inclusion
- identify included pseudo-exon
- use ENCODE data for identification
- describe effect of ASO on OPA1 protein production
- describe effect of ASO on OPA1 mRNA production
- explain NMD exon length
- describe NMD exon composition
- explain frameshift and PIC
- describe method of modulating OPA1 protein expression
- explain target portion of pre-mRNA for inclusion of coding exon

### Exclusion of Both NMD Exon and Coding Exon

- describe method of modulating expression of target protein
- specify agent binding to targeted portion of pre-mRNA
- detail targeted portion of pre-mRNA proximal to coding exon
- detail targeted portion of pre-mRNA proximal to NMD exon
- provide example of modulating OPA1 protein expression
- specify sequence identity of coding exon and NMD exon
- describe exclusion of coding exon and NMD exon from pre-mRNA
- quantify increase in exclusion of coding exon and NMD exon
- quantify increase in level of processed mRNA and OPA1 protein
- describe functionality of OPA1 protein expressed from processed mRNA

### Therapeutic Agents

- introduce therapeutic agents
- define NIE repressor agent
- describe polynucleic acid polymer composition
- motivate method of treatment or prevention
- describe binding to NMD exon region
- describe binding to NMD exon-activating regulatory sequence
- describe reduction of NMD exon inclusion
- describe increase of functional OPA1 protein levels
- describe binding to coding exon region
- describe exclusion of coding exon
- describe polynucleic acid polymer length
- describe sequence complementarity
- describe hybridization conditions
- describe sequence identity
- define ASO hybridization
- describe Tm and stringent hybridization conditions
- define complementary oligomers
- describe sequence complementarity of ASO
- define ASO composition
- describe backbone structure and linkages
- describe modified nucleobases
- describe stereochemistry of phosphorus internucleotide linkages
- describe diastereomeric purity of ASO
- describe Rp and Sp configurations of phosphorus internucleotide linkages
- describe sequence identity of ASO
- describe sugar moiety modifications
- describe uniform and mixed modifications
- describe examples of ASO modifications
- describe methods of synthesizing ASOs
- define nucleic acid directions
- describe ASO binding to OPA1 pre-mRNA downstream
- specify ASO binding regions downstream
- describe ASO binding to OPA1 pre-mRNA upstream
- specify ASO binding regions upstream
- describe ASO binding to OPA1 pre-mRNA at 3' splice site
- specify ASO binding regions at 3' splice site
- describe ASO binding to OPA1 pre-mRNA at 5' splice site
- specify ASO binding regions at 5' splice site
- describe targeted portion of OPA1 pre-mRNA
- specify ASO length
- provide examples of ASO lengths
- specify specific ASO lengths
- define therapeutic agents
- describe conjugation of antisense oligonucleotides
- specify targeted nucleic acid
- introduce pharmaceutical compositions
- describe preparation of pharmaceutical formulations
- list possible dosage forms
- describe therapeutic agents
- introduce combination therapies
- motivate treatment of subjects
- describe administration to individuals
- discuss treatment of diseases
- motivate OPA1 deficiency treatment
- describe therapeutic agents
- introduce gene editing tools
- discuss administration routes
- motivate blood-brain barrier penetration
- evaluate treatment improvement

### Methods of Identifying Additional ASOs That Induce Exon Skipping

- identify ASOs inducing exon skipping
- design ASO walk for target region
- screen ASOs for exon skipping effects
- refine target region with ASO micro-walk
- assess splicing-inducing effects of ASOs
- test ASOs in vivo using animal models
- validate NMD-inducing exon with NMD inhibitor

### Specific Embodiments (a)

- define method of treating Optic atrophy type 1
- specify target protein as OPA1
- describe method of increasing OPA1 protein expression
- exclude non-sense mediated RNA decay-inducing exon
- specify target protein without non-sense mediated RNA decay-inducing exon
- describe full-length target protein
- specify antisense oligomer as therapeutic agent
- describe pre-mRNA as target
- specify nucleus as location of mRNA
- describe correction of target protein deficiency
- specify cells from subject with OPA1-related condition
- describe haploinsufficiency of target protein
- specify disorder resulting from target protein deficiency
- describe antisense oligomer binding to targeted portion of NMD exon mRNA
- define specific embodiments
- specify therapeutic agents
- describe antisense oligomers
- outline pharmaceutical compositions
- detail methods of treatment
- specify administration methods
- describe target proteins
- outline mRNA sequences
- specify exon-intron junctions
- describe backbone modifications
- define specific embodiments
- specify targeted portion of NMD exon mRNA
- describe antisense oligomer composition
- specify sequence identity of antisense oligomer
- describe method of inducing processing of deficient OPA1 mRNA transcript
- describe method of treating a subject having a condition caused by a deficient amount or activity of OPA1 protein
- describe method of treating Optic atrophy type 1
- describe method of increasing expression of OPA1 protein
- describe method of modulating expression of a target protein
- describe method of treating a disease or condition
- specify therapeutic agent binding
- specify targeted portion location
- specify genomic site
- specify targeted portion composition
- specify embodiments
- define mRNA encoding target protein
- specify targeted portion of mRNA
- describe agent properties
- specify therapeutic agent effects
- describe disease or condition
- specify therapeutic agent administration
- describe therapeutic agent composition
- specify therapeutic agent length
- describe therapeutic agent complementarity
- specify assessment of mRNA level
- specify subject type
- specify cell type
- describe administration methods

### Further Specific Embodiments

- define method of modulating OPA1 protein expression
- specify agent binding to pre-mRNA
- specify agent modulating splicing factor binding
- specify targeted portion of pre-mRNA proximal to NMD exon
- specify targeted portion of pre-mRNA upstream of NMD exon
- specify targeted portion of pre-mRNA downstream of NMD exon
- specify targeted portion of pre-mRNA within intronic region
- specify targeted portion of pre-mRNA overlapping with NMD exon
- specify targeted portion of pre-mRNA within NMD exon
- specify targeted portion of pre-mRNA with consecutive nucleotides
- specify NMD exon sequence identity
- specify OPA1 protein expression
- specify method results in increased OPA1 protein expression
- specify embodiments
- define targeted portion of pre-mRNA
- specify location of targeted portion
- describe relationship to coding exon
- specify sequence identity to SEQ ID NO
- describe effect on OPA1 protein expression
- describe functional properties of OPA1 protein
- specify agent composition
- describe gene editing molecule
- outline method of modulating OPA1 protein expression
- describe method of modulating target protein expression
- specify embodiment 90
- modify embodiment 90
- specify location of targeted portion
- specify characteristics of coding exon
- specify location of targeted portion relative to coding exon
- specify location of targeted portion relative to NMD exon
- specify characteristics of NMD exon
- specify effect of agent on exclusion of coding exon
- specify effect of agent on exclusion of NMD exon
- specify effect of agent on level of processed mRNA
- specify effect of agent on expression of target protein
- specify antisense oligomer sequences
- describe gene editing molecules
- specify backbone modifications
- describe sugar moiety modifications
- specify nucleobase ranges
- describe viral vectors
- specify mRNA level assessment
- describe therapeutic agents
- specify pharmaceutical compositions
- describe antisense oligomer binding
- specify administration routes
- describe treatment methods

## EXAMPLES

- provide examples of NMD-inducing exon inclusion events

### Example 1: Identification of NMD-inducing Exon Inclusion Events in Transcripts by RNAseq using Next Generation Sequencing

- identify NMD exon inclusion events using RNAseq

### Example 2: Confirmation of NMD Exon via Cycloheximide Treatment

- confirm NMD exon via cycloheximide treatment

### Example 3: NMD Exon Region ASO Walk

- perform ASO walk for NMD exon region

### Example 4: NMD Exon Region ASO Walk Evaluated by RT-PCR

- evaluate ASO walk sequences by RT-PCR

### Example 5: NMD Exon Region ASO Microwalk Evaluated by RT-qPCR

- evaluate ASO microwalk sequences by RT-qPCR

### Example 6: Dose-Dependent Effect of Selected ASO in CXH-Treated Cells

- show dose-dependent effect of selected ASO

### Example 7: Intravitreal (IVT) Injection of Selected ASOs

- inject ASOs intravitreally

### Example 8: Intracerebroventricular (ICV) Injection of Selected ASOs

- inject ASOs intracerebroventricularly

### Example 9: OPA1 Non-Productive Splicing Event Identification and Validation

- identify nonsense mediated decay exon inclusion event
- evaluate true abundance of event using cycloheximide
- validate presence of NMD exon in ocular cell lines
- show increase in OPA1 transcripts containing NMD exon
- describe FIG. 8
- introduce Example 10
- show reverse transcription PCR data from primate eyes
- quantify NMD exon abundance at different ages
- introduce Example 11
- describe antisense oligomers reducing non-productive splicing
- describe ASO treatment and RNA analysis
- show gel image and quantification of qPCR Ct values
- show data on OPA1 expression level after ASO treatment
- describe microwalk experiment and RT-qPCR analysis
- show data from experiments with 18-mer ASOs
- show data from experiments with 16-mer ASOs
- describe transfection dose response experiment
- show dose response curves of relative OPA1 transcript amounts
- describe ATP measurement experiment
- show ATP level data and OPA1 protein data
- describe experiment with OPA1 haploinsufficient HEK293 cells
- show OPA1 protein data and ATP level data
- describe experiment with patient fibroblast cells
- show data on OPA1 mRNA and protein levels in patient cells
- describe effects of ASO-14 on OPA1 expression and mitochondrial bioenergetics

